Synchron
Last updated Apr 13, 2026
Thesis
Synchron has developed an endovascular brain-computer interface (BCI). A device implanted via blood vessels rather than through open brain surgery. This approach dramatically reduces the risk profile compared to competitors like Neuralink that require invasive craniotomy. The company has received FDA authorization for clinical trials in the United States and has already implanted devices in human patients, generating real clinical data on safety and efficacy. The investor base is exceptionally strong. Gates Foundation and Bezos Expeditions, representing two of the world's most prominent technology and healthcare investors. Synchron is accessible to accredited investors via secondary markets through platforms like Forge Global and EquityZen. The BCI sector as a whole saw funding triple to $867M in 2025, indicating accelerating institutional interest in neural interface technology. The endovascular approach is Synchron's key differentiator. While it may offer lower bandwidth than direct cortical implants (Neuralink, Paradromics), the dramatically improved safety profile, requiring no brain surgery, positioning it for broader clinical adoption and potentially faster regulatory approvals. The primary risks are the nascent BCI market with uncertain commercial timelines, competition from Neuralink's higher-profile and better-funded program, and the inherent illiquidity of private company shares.
Catalysts
- +FDA-authorized clinical trials ongoing with human patients implanted and generating real clinical data
- +BCI sector funding tripled to $867M in 2025, indicating accelerating institutional momentum
- +Endovascular approach avoids open brain surgery. Differentiated safety profile enables broader clinical adoption
Risks
- -Private company with limited liquidity. Accredited investors only via Forge Global/EquityZen secondary markets
- -BCI market still nascent with uncertain commercial timelines and regulatory hurdles
- -Neuralink competition with significantly more funding, visibility, and potentially higher bandwidth
Research & Sources
5 sourcesCommon questions
What could drive Synchron higher?
FDA-authorized clinical trials ongoing with human patients implanted and generating real clinical data BCI sector funding tripled to $867M in 2025, indicating accelerating institutional momentum Endovascular approach avoids open brain surgery.
What are the main risks of holding Synchron?
Private company with limited liquidity. Accredited investors only via Forge Global/EquityZen secondary markets BCI market still nascent with uncertain commercial timelines and regulatory hurdles Neuralink competition with significantly more funding, visibility, and potentially higher bandwidth
Is Synchron undervalued?
Early Thunder's valuation gap signal puts Synchron at 90 out of 100, where a higher number means a wider gap between the current price and what the fundamentals suggest. The thesis and competitive sections above show the full read.
Risk Disclosure
Synchron. Private market investments are illiquid and carry extreme risk. Past patterns do not predict future results. Always do your own research and consult a qualified advisor before investing.